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This data set is composed of transcriptomics analyses of (i) liver
samples from patients suffering from acetaminophen-induced acute
liver failure (ALF) and (ii) hepatic cell systems exposed to acet-
aminophen and their respective controls. The in vitro systems include
widely employed cell lines i.e. HepaRG and HepG2 cells as well as a
novel stem cell-derived model i.e. human skin-precursors-derived
hepatocyte-like cells (hSKP-HPC). Data from primary human hepa-
tocytes was also added to the data set “Open TG-GATEs: a large-scale
toxicogenomics database” (Igarashi et al., 2015) [1]. Changes in gene
expression due to acetaminophen intoxication as well as comparative
information between human in vivo and in vitro samples are pro-
vided. The microarray data have been deposited in NCBI's Gene
Expression Omnibus and are accessible through GEO Series accession
number GEO: GSE74000. The provided data is used to evaluate the
predictive capacity of each hepatic in vitro system and can be directly
compared with large-scale publically available toxicogenomics data-
bases. Further interpretation and discussion of these data feature in
the corresponding research article “Toxicogenomics-based prediction
of acetaminophen-induced liver injury using human hepatic cell
systems” (Rodrigues et al., 2016) [2].vier Inc. This is an open access article under the CC BY license
/j.toxlet.2015.10.014
.ac.be (R.M. Rodrigues).
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(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Biology
ore speciﬁc sub-
ject areaToxicologyype of data Tables and Figures
ow data was
acquiredAmpliﬁed RNA fragments were hybridized to Affymetrix Human Genome U133
plus 2.0 array and scanned with Affymetrix Gene-Chip Scanner-3000-7G.
Background correction, summarization (median polish) and normalization
(quantile) were done by Robust Multi-array Analysis (RMA) using RMAExpress
v1.0.5 software. Ingenuity Pathway Analysis software (version December 2014)
was used for functional analyses and set-up of predictive diagrams.ata format RAW/Analyzed
xperimental
factorsAll hepatic in vitro models were exposed to their corresponding acetaminophen-
based IC10 concentrations and vehicle controls 24 hours prior to sampling.
Acetaminophen-based cytotoxicity was ﬁrst assessed in vitro using the MTT
viability assay. The 24 hour IC10 value for each cell type (HepG2, HepaRG and
hSKP-HPC) was determined by 4-parameter logistic nonlinear regression ana-
lysis of the obtained dose response curves.xperimental
featuresTotal RNA was extracted from samples exposed to acetaminophen (IC10) and
their respective vehicle controls as well as from clinical samples of
acetaminophen-induced acute liver failure (ALF) and healthy livers. RAW tran-
scriptomics data were generated by Affymetrix microarray technology. Changes
in gene expression due to acetaminophen-induced toxicity for each of the
hepatic in vitro models as well as for clinical samples of ALF were calculated as
fold change of their respective vehicle controls. Data obtained from all hepatic
in vitro models exposed to acetaminophen (IC10) were compared to clinical
samples of acetaminophen-induced ALF. Ingenuity Pathway Analysis software
was used to build an ALF prediction diagram and to evaluate the predictive
capacity of each hepatic in vitro system.ata source
locationDepartment of in vitro Toxicology and Dermato-Cosmetology (IVTD), Vrije Uni-
versiteit Brussel (VUB), Brussels, Belgiumata accessibility Data is within this article. RAW microarray data have been deposited in NCBI's
Gene Expression Omnibus and are accessible through GEO Series accession
number GEO: GSE74000.Value of the data
 These data can be used as a reference data set for predictive analysis of acetaminophen-induced
liver injury.
 Transcriptomics datasets were obtained from scarcely available liver samples of patients suffering
from acetaminophen-induced acute liver failure as well as from healthy individuals. They are
mostly of interest for the scientiﬁc community working on human hepatic toxicity.
 Transcriptomics data of the most widely employed hepatic in vitro systems (exposed to acet-
aminophen and corresponding controls) are also provided. These data can be used in comparative
studies in which other hepatic cell systems are used.
Fig. 1. Prediction diagram for the toxicity gene class “Necrosis of Liver”. The selection of genes was based on the signiﬁcantly
modulated molecules of this gene class in the ALF samples versus control samples. For this selection of genes, the “Necrosis of
Liver” function was activated for hHEP, HepaRG and hSKP-HPC, but not for HepG2.
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Table 1
Modulation of genes (fold change relative to respective controls) of the “Damage of Liver” gene class selected for APAP-induced
ALF samples.
Damage of liver genes ALF hSKP-HPC hHEP HepaRG HepG2
NCF1 3.6 1.1 1.0 1.1 1.0
FASLG 2.9 1.1 1.3 1.1 1.3
MED1 2.7 1.4 1.2 1.3 1.2
CD44 2.1 2.4 3.2 3.0 3.2
SH3BP5 2.0 1.6 3.0 2.6 3.0
FLT1 2.6 2.2 1.6 1.2 1.6
CTNNB1 3.6 1.7 1.2 1.3 1.2
ALB 3.7 8.1 1.7 7.4 1.7
SMAD4 3.7 1.8 1.5 1.5 1.5
PAWR 3.8 2.7 1.3 2.6 1.3
IFNGR1 3.9 1.3 1.5 2.4 1.5
BPNT1 4.2 1.1 2.1 1.8 2.1
TLR3 4.5 1.3 3.6 21.6 3.6
CFH 5.6 1.0 1.4 3.1 1.4
EGR1 7.2 33.9 2.3 6.1 2.3
RDX 8.7 1.3 1.6 1.1 1.6
SERPING1 10.1 1.1 1.0 1.3 1.0
GCLC 11.8 2.8 2.7 1.4 2.7
IL6ST 14.3 1.5 2.9 1.3 2.9
SAA2 16.1 4.0 1.0 1.4 1.0
IGF1 104.2 48.5 7.0 16.0 7.0
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Gene expression data obtained by microarray are provided from (1) clinical samples obtained from
patients suffering from acetaminophen-induced acute liver failure and healthy liver samples and from
(2) the most widely employed hepatic systems (HepaRG cells, HepG2 cells and primary human
hepatocytes) as well as a recently introduced stem cell-based hepatic model (human skin-precursors-
derived hepatocyte-like cells (hSKP-HPC)) exposed to acetaminophen (and respective controls). All
data were obtained using whole genome microarray arrays (Affymetrix Human Genome U133
plus 2.0).2. Experimental design, materials and methods
Samples were isolated from either clinical liver samples from patients suffering from
acetaminophen-induced acute liver failure (ALF) and samples of healthy livers or various hepatic
in vitromodels, i.e. HepaRG, HepG2 and hSKP-HPC. Corresponding vehicle controls were also included
in the analysis [2].
The following in vitro and in vivo samples were analyzed:
(1) HepG2 cells exposed to IC10 concentration (2 mM) of acetaminophen and untreated controls:
n¼3 biological replicates for each condition.
(2) HepaRG cells exposed to IC10 concentration (13 mM) of acetaminophen and untreated controls:
n¼3 biological replicates for each condition.
(3) hSKP-HPC exposed to IC10 concentration (18 mM) of acetaminophen and untreated controls: n¼3
biological replicates for each condition: prior to acetaminophen exposure, hSKP were isolated,
cultured and differentiated into hSKP-HPC as previously described [3,4].
(4) Primary human hepatocytes exposed to IC10 concentration (5 mM) of acetaminophen and
untreated controls available through Open TG-GATEs database: n¼2 biological replicates for each
condition [1].
Table 2
Modulation of genes (fold change relative to respective controls) of the “Necrosis of Liver” gene class selected for APAP-induced
ALF samples.
Liver necrosisgenes ALF hSKP-HPC hHEP HepaRG HepG2
TGFB1 4.82 1.20 3.50 2.01 1.41
STK4 4.80 1.83 1.43 2.02 1.39
NCF1 3.62 1.07 1.00 1.14 1.01
FASLG 2.91 1.07 1.26 1.08 1.14
MED1 2.69 1.38 1.20 1.26 1.06
BUB1 2.47 1.89 4.12 4.89 1.20
TNFSF12 2.25 1.73 1.36 1.04 1.11
RIPK3 2.24 1.30 1.35 1.13 1.04
BAK1 2.12 1.05 1.05 1.26 1.21
SH3BP5 2.04 1.56 2.95 2.62 1.68
API5 2.16 1.20 1.92 2.10 1.16
MAPK9 2.53 1.21 1.91 3.17 1.24
IRF2 2.67 1.29 1.28 1.01 1.04
ARF6 2.75 1.44 1.19 1.44 1.15
HSPD1 2.88 1.92 1.53 1.27 1.60
AGA 2.89 1.21 1.19 1.11 1.58
MAPK8 3.29 2.82 1.73 1.88 1.41
CFLAR 3.49 2.66 1.72 1.82 1.57
PIK3R1 3.52 1.27 1.31 1.35 1.19
NF1 3.66 1.77 1.22 1.28 1.28
STAT1 3.81 1.50 1.34 1.35 1.51
XIAP 3.92 1.38 1.50 1.50 1.14
JUN 3.94 1.91 1.44 2.77 1.25
C3 4.04 1.07 1.56 1.30 1.13
SEPP1 4.04 2.57 1.72 1.73 1.24
TIMP3 4.43 8.65 2.47 1.48 1.30
TBK1 4.50 1.86 1.04 1.24 1.03
IL33 4.66 1.73 1.14 1.39 1.02
PROC 4.84 1.01 1.80 1.16 1.26
F11 5.20 1.13 1.53 1.68 1.14
CFH 5.61 1.02 1.40 3.10 1.13
FGA 6.35 1.10 1.65 3.13 1.62
RB1CC1 6.44 1.55 1.50 1.26 1.18
PROS1 9.55 1.14 1.66 1.71 1.11
NR1H4 9.81 1.21 2.26 8.36 2.57
IL6ST 14.33 1.50 2.88 1.25 1.24
IGF1 104.24 48.52 6.98 15.97 1.17
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liver samples: n¼3 biological replicates for ALF samples and n¼2 biological replicates for
healthy liver.
Total RNA isolation was conducted using the GenElute Mammalian Total RNA Puriﬁcation Mini-
prep Kit (Sigma-Aldrich) following the manufacturer's instructions.
Total RNA (100 ng) was used for ampliﬁcation and in vitro transcription using the Genechip 3’ IVT
Express Kit following the manufacturer's instructions (Affymetrix). The ampliﬁed RNA was puriﬁed
with magnetic beads and 15 μg Biotin-aRNA was treated with fragmentation reagent. 12.5 μg frag-
mented aRNA was hybridized to Affymetrix Human Genome U133 plus 2.0 arrays along with a
hybridization cocktail solution and then placed in a Genechip Hybridization Oven-645 (Affymetrix)
rotating at 60 rpm at 45 °C for 16 h. After incubation, arrays were washed on a Genechip Fluidics
Station-450 (Affymetrix) and stained with the Affymetrix HWS kit as indicated by the manufacturer's
protocols (Affymetrix).
The chips were scanned with an Affymetrix Gene-Chip Scanner-3000-7G and the quality control
matrices were conﬁrmed with the Affymetrix GCOS software following the manufacturer's guidelines.
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tiarray Analysis (RMA). Changes in gene expression due to acetaminophen-induced toxicity for each
of the hepatic in vitro models as well as for clinical samples of ALF were calculated as fold change of
their respective controls. Ingenuity Pathway Analysis software (version December 2014; Qiagen) was
used to build an ALF prediction diagram based on the microarray data of patients suffering from
acetaminophen-induced liver failure. This was then used to evaluate the predictive capacity of each
hepatic in vitro system by comparing the acetaminophen-induced gene expression modulation to
clinical samples of acetaminophen-induced ALF.
In Fig. 1, the data are shown of the four investigated hepatic in vitro models in which gene
modulation due to acetaminophen-induced toxicity was assessed. It depicts a prediction diagram for
the toxicity gene class “Necrosis of Liver”. Table 1 shows a selection of genes corresponding to the
“Damage of Liver” gene class with separate gene expression modulation values for each investigated
hepatic system. This data accompanies the prediction chart “Damage of Liver” published in the
research article complimentary to the current data in brief article [1]. Table 2 shows a selection of
genes corresponding to the “Necrosis of Liver” prediction chart indicated in Fig. 1. The selection of the
genes in Tables 1 and 2 as well as the corresponding prediction charts were based on the differential
gene expression between the liver samples of patients suffering from acetaminophen-induced liver
failure and samples obtained from healthy livers. The cut-off was set at minimum 2-fold expression
divergence and statistical signiﬁcance with p-value o0.05 (Fisher's exact).Acknowledgments
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